Previous studies have reported PD‐L1 TPS <1% in 42.4%–62.7%, 1%–49% in 25.55%–37.6%, and ≥ 50% in 9.4%–21.2% of lung adenocarcinoma patients.15, 23, 33. Here, CD274 is linked to lung adenocarcinoma.